PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Ogilvy Public Relations

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations - The Clinical Pharmacology Unit (CPU) of GVK Biosciences (GVK BIO) received approvals from all major regulatory bodies globally including USFDA, AFSAAPS, WHO and ANVISA
The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations

 

NewswireToday - /newswire/ - Hyderabad, Andhra Pradesh, India, 2008/01/07 - The Clinical Pharmacology Unit (CPU) of GVK Biosciences (GVK BIO) received approvals from all major regulatory bodies globally including USFDA, AFSAAPS, WHO and ANVISA.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The approvals open global markets to GVK BIO’s clients in the US, Europe and Latin American countries in addition to the domestic sector.

Manni Kantipudi, President of GVK BIO stated, “The approvals validate GVK BIO’s high quality systems and practices”.

As a first step, GVK BIO has expanded and built a new state-of-the-art Bioanalytical facility in addition to the existing one to cater to the growing business demands. GVK BIO is also setting up its own Clinical Laboratory and aims for an early accreditation.
“GVK BIO aims to be a full service Clinical Research Organization offering services from BA/BE to Phase I through Phase IV Clinical Trials”, said Mr. G.V.Sanjay Reddy, Managing Director, GVK BIO.

Set up in 2001, GVK BIO is a leading CRO in India. GVK BIO started offering Bioavailability/Bioequivalence(BA/BE) services in 2004 and in a very short time received major accreditations from international regulatory authorities such as ANVISA (Brazil) and AFSAAPS (French) and the US FDA. The US FDA has inspected the facilities twice and approved several BA/BE studies conducted by GVK BIO. The BA/BE facility was also inspected and cleared by WHO after a recent audit of one of the studies. GVK BIO’s BA/BE Centre was requalified by ANVISA (Brazilian Regulatory Body) for the third consecutive year.

About Clinical Pharmacology Unit (CPU)
The Clinical Pharmacology Unit (CPU) located at Hyderabad, is one of the largest units in India for Bioavailability and Bioequivalence studies with state-of-the-art infrastructure to cater to global regulatory requirements. The SBU with 144 beds and a comprehensive volunteer database has the capability of undertaking studies for special population and dosage forms like injectables in addition to the conventional studies, which sets it apart from the competition. As of now, CPU has conducted around 300 studies of which more than 50 studies are for USFDA submission.

About GVK BIO

GVK Biosciences, India’s premier Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. The company accelerates the Drug Discovery and Development process of its customers through science and innovation. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.

For any further information, please contact:
Sharada Alvakonda
Dy. General Manager – Corporate Communications
GVK Biosciences Private Ltd
Hyderabad
T: +91 40 66929999 - E: sharada[.]gvkbio.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Ogilvy Public Relations

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


The GVK BIO Clinical Pharmacology Unit Granted Major Accreditations

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sreekar Reddy - Ogilvy.com 
+91 98 66110032 sreekar.reddy[.]ogilvy.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ogilvy Public Relations securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Ogilvy Public Relations / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)